- Home
- SLSN vs LYEL Comparison
SLSN vs LYEL Comparison
Compare SLSN & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLSN
- LYEL
- Stock Information
- Founded
- SLSN 1989
- LYEL 2018
- Country
- SLSN United States
- LYEL United States
- Employees
- SLSN N/A
- LYEL N/A
- Industry
- SLSN
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- SLSN
- LYEL Health Care
- Exchange
- SLSN NYSE
- LYEL Nasdaq
- Market Cap
- SLSN 218.7M
- LYEL 207.7M
- IPO Year
- SLSN N/A
- LYEL 2021
- Fundamental
- Price
- SLSN $3.36
- LYEL $0.43
- Analyst Decision
- SLSN
- LYEL Sell
- Analyst Count
- SLSN 0
- LYEL 2
- Target Price
- SLSN N/A
- LYEL $1.00
- AVG Volume (30 Days)
- SLSN 114.4K
- LYEL 632.8K
- Earning Date
- SLSN 05-05-2025
- LYEL 05-20-2025
- Dividend Yield
- SLSN N/A
- LYEL N/A
- EPS Growth
- SLSN N/A
- LYEL N/A
- EPS
- SLSN 0.05
- LYEL N/A
- Revenue
- SLSN $57,104,000.00
- LYEL $61,000.00
- Revenue This Year
- SLSN N/A
- LYEL N/A
- Revenue Next Year
- SLSN N/A
- LYEL N/A
- P/E Ratio
- SLSN $60.15
- LYEL N/A
- Revenue Growth
- SLSN 51.44
- LYEL N/A
- 52 Week Low
- SLSN $1.56
- LYEL $0.39
- 52 Week High
- SLSN $3.36
- LYEL $2.88
- Technical
- Relative Strength Index (RSI)
- SLSN N/A
- LYEL 42.10
- Support Level
- SLSN N/A
- LYEL $0.41
- Resistance Level
- SLSN N/A
- LYEL $0.51
- Average True Range (ATR)
- SLSN 0.00
- LYEL 0.05
- MACD
- SLSN 0.00
- LYEL 0.00
- Stochastic Oscillator
- SLSN 0.00
- LYEL 28.70
About SLSN SOLESENCE INC
Solesence Inc is a scientifically driven health care solutions company across beauty and life science categories, protecting skin from environmental aggressors and enhancing the aesthetic appeal of healthy products. The group is engaged in the beauty category that develops and manufactures clean, inclusive, mineral-based skincare and makeup products at the forefront of skin health. Its brands are Stress Defense, Kleair, and Bloom.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.